Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of February 2025. The filing details a specific share repurchase executed on February 26, 2025, acting through corporate stockbroker Citigroup Global Markets Limited. The Company is a foreign private issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on share buyback activity and does not provide revenue, profit, cash flow, or debt metrics.
- Shares Purchased (Feb 26, 2025): 800,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,464.00p; highest price paid was 1,499.50p.
- Volume-Weighted Average Price (VWAP): 1,477.01p.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: Following this purchase, the Company holds 171,681,355 ordinary shares in treasury.
- Shares in Issue: 4,143,485,716 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,143,485,716.
Material Changes and Program Status
The purchase on February 26, 2025, was part of the Company's existing buyback programme. It was effected pursuant to a non-discretionary agreement entered into with the Broker on February 24, 2025. Since the commencement of this specific agreement on February 24, 2025, the Company has purchased an aggregate of 2,611,052 ordinary shares. The filing does not disclose material changes to financial performance compared to prior periods, as it is a transaction report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK cautions that any projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2023 and its Q4 Results for 2024. No new guidance or management commentary regarding future financial performance is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (171,681,355) against the Company's latest capital structure disclosures.
- Confirm the remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Review the referenced Form 20-F (2023) and Q4 2024 results for detailed risk factors and financial performance context not included in this transaction report.
- Monitor subsequent filings for updates on the buyback programme status and total shares repurchased.